Biote Announces Purchase of Shares by Directors and CEO
Board Confidence in Biote: Several members of Biote's Board of Directors and CEO Bret Christensen have purchased approximately 260,000 shares of the company's stock, reflecting their confidence in Biote's business strategy and leadership.
Biote's Mission and Market: Biote focuses on preventive healthcare through personalized hormone optimization and wellness solutions, training medical providers to address early aging indicators in an underserved market.
Trade with 70% Backtested Accuracy
Analyst Views on BTMD
About BTMD
About the author
Biote Corp Reports Decrease in Q3 Earnings
- Earnings Decline: biote Corp reported a third-quarter profit of $8.19 million, down from $10.70 million in the same period last year.
- Earnings Per Share: The earnings per share (EPS) decreased to $0.22 from $0.33 year-over-year.
- Revenue Drop: The company's revenue fell by 6.7% to $47.96 million, compared to $51.38 million in the previous year.
- Financial Overview: Key financial metrics indicate a decline in both earnings and revenue for biote Corp compared to the prior year.
Capricor (CAPR) Rises 5.3%: Could This Signal More Upside Ahead?
Capricor Therapeutics Stock Performance: Capricor Therapeutics (CAPR) shares rose 5.3% to $6.52, driven by a positive regulatory update on its Deramiocel program for Duchenne muscular dystrophy, which may expedite the drug's market entry.
Earnings Expectations and Market Position: The company is projected to report a quarterly loss of $0.54 per share, with revenues expected to increase by 6.2% year-over-year. The consensus EPS estimate has remained stable, indicating potential stock price movements may depend on future earnings revisions.
Biote Names Rich Barrera to Board of Directors
New Board Member Announcement: Biote Corp. has appointed Rich Barrera to its Board of Directors, bringing over 20 years of investment management experience and alignment with the company's growth strategy.
Company Overview: Biote focuses on preventive health care through personalized hormone optimization and wellness solutions, aiming to address aging conditions and enhance clinic success for practitioners.
Why Meta Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket
Meta Platforms Earnings Report: Meta Platforms, Inc. shares rose 6.1% in pre-market trading after reporting first-quarter earnings of $6.43 per share, significantly exceeding analyst expectations of $5.21, and projecting second-quarter revenue between $42.5 billion and $45.5 billion.
Stock Movements: Several stocks experienced notable changes in pre-market trading, with NanoVibronix, Inc. rising 81.8% and biote Corp. falling 46%, while Microsoft Corporation also saw an 8.2% increase following better-than-expected financial results.
Insider Purchase: Director at $BTMD Buys 50,000 Shares
Insider Trading Activity: Andrew R. Heyer, a director at $BTMD, purchased 50,000 shares for approximately $197,380, increasing his holdings by 3.4%. In the past six months, all eight insider trades reported were purchases, indicating strong insider confidence in the stock.
Institutional and Analyst Sentiment: 52 institutional investors have recently increased their positions in $BTMD, while only 35 decreased theirs. Analysts have issued one buy rating with no sell ratings, suggesting a generally positive outlook on the stock.
Insider Purchase: Director at $BTMD Buys 107,794 Shares
Insider Trading Activity: Marc D Beer, a director at $BTMD, purchased 107,794 shares for approximately $417,162, increasing his holdings. In the past six months, all four insider trades reported were purchases, with no sales recorded.
Institutional and Analyst Insights: 52 institutional investors increased their positions in $BTMD stock, while 35 decreased theirs. Analysts have issued one buy rating and no sell ratings on the stock recently.
Biote Corp Reports Decrease in Q3 Earnings
- Earnings Decline: biote Corp reported a third-quarter profit of $8.19 million, down from $10.70 million in the same period last year.
- Earnings Per Share: The earnings per share (EPS) decreased to $0.22 from $0.33 year-over-year.
- Revenue Drop: The company's revenue fell by 6.7% to $47.96 million, compared to $51.38 million in the previous year.
- Financial Overview: Key financial metrics indicate a decline in both earnings and revenue for biote Corp compared to the prior year.
Capricor (CAPR) Rises 5.3%: Could This Signal More Upside Ahead?
Capricor Therapeutics Stock Performance: Capricor Therapeutics (CAPR) shares rose 5.3% to $6.52, driven by a positive regulatory update on its Deramiocel program for Duchenne muscular dystrophy, which may expedite the drug's market entry.
Earnings Expectations and Market Position: The company is projected to report a quarterly loss of $0.54 per share, with revenues expected to increase by 6.2% year-over-year. The consensus EPS estimate has remained stable, indicating potential stock price movements may depend on future earnings revisions.
Biote Names Rich Barrera to Board of Directors
New Board Member Announcement: Biote Corp. has appointed Rich Barrera to its Board of Directors, bringing over 20 years of investment management experience and alignment with the company's growth strategy.
Company Overview: Biote focuses on preventive health care through personalized hormone optimization and wellness solutions, aiming to address aging conditions and enhance clinic success for practitioners.
Why Meta Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket
Meta Platforms Earnings Report: Meta Platforms, Inc. shares rose 6.1% in pre-market trading after reporting first-quarter earnings of $6.43 per share, significantly exceeding analyst expectations of $5.21, and projecting second-quarter revenue between $42.5 billion and $45.5 billion.
Stock Movements: Several stocks experienced notable changes in pre-market trading, with NanoVibronix, Inc. rising 81.8% and biote Corp. falling 46%, while Microsoft Corporation also saw an 8.2% increase following better-than-expected financial results.
Insider Purchase: Director at $BTMD Buys 50,000 Shares
Insider Trading Activity: Andrew R. Heyer, a director at $BTMD, purchased 50,000 shares for approximately $197,380, increasing his holdings by 3.4%. In the past six months, all eight insider trades reported were purchases, indicating strong insider confidence in the stock.
Institutional and Analyst Sentiment: 52 institutional investors have recently increased their positions in $BTMD, while only 35 decreased theirs. Analysts have issued one buy rating with no sell ratings, suggesting a generally positive outlook on the stock.
Insider Purchase: Director at $BTMD Buys 107,794 Shares
Insider Trading Activity: Marc D Beer, a director at $BTMD, purchased 107,794 shares for approximately $417,162, increasing his holdings. In the past six months, all four insider trades reported were purchases, with no sales recorded.
Institutional and Analyst Insights: 52 institutional investors increased their positions in $BTMD stock, while 35 decreased theirs. Analysts have issued one buy rating and no sell ratings on the stock recently.
